Research on prostate cancer cell lines (LNCaP, DU145, PC-3) has demonstrated fisetin’s effectiveness in reducing tumor growth by competing with AR ligands, lowering AR stability, and enhancing TRAIL-induced apoptosis [188]. The gene discussed is AR; the disease is neoplasm.